Oxinas Partners Wealth Management LLC Purchases Shares of 10,643 Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)

Oxinas Partners Wealth Management LLC purchased a new stake in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 10,643 shares of the company’s stock, valued at approximately $103,000.

Several other large investors also recently made changes to their positions in GNOM. Flow Traders U.S. LLC acquired a new stake in shares of Global X Genomics & Biotechnology ETF in the third quarter valued at approximately $936,000. Sanctuary Advisors LLC acquired a new position in shares of Global X Genomics & Biotechnology ETF during the second quarter valued at approximately $590,000. Rockefeller Capital Management L.P. acquired a new position in shares of Global X Genomics & Biotechnology ETF during the third quarter valued at approximately $205,000. Centaurus Financial Inc. acquired a new position in shares of Global X Genomics & Biotechnology ETF during the second quarter valued at approximately $146,000. Finally, Atria Investments Inc acquired a new position in shares of Global X Genomics & Biotechnology ETF during the third quarter valued at approximately $122,000. Institutional investors and hedge funds own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Price Performance

NASDAQ GNOM opened at $9.98 on Wednesday. Global X Genomics & Biotechnology ETF has a 12 month low of $9.50 and a 12 month high of $12.53. The firm has a market capitalization of $69.56 million, a PE ratio of -4.26 and a beta of 1.03. The company’s 50 day simple moving average is $10.13 and its 200 day simple moving average is $10.75.

Global X Genomics & Biotechnology ETF Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.